Clinical non-inferiority between transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) has previously been demonstrated in a patient cohort with severe aortic stenosis at lower surgical risk. However, the cost-effectiveness of TAVI is uncertain in this patient population.
